BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.35%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$846M
AUM Growth
+$846M
(+13%)
Cap. Flow
+$40.5M
Cap. Flow
% of AUM
4.78%
Top 10 Holdings %
Top 10 Hldgs %
28.99%
Holding
143
New
11
Increased
57
Reduced
23
Closed
11
Top Buys
| 1 |
Integra LifeSciences
IART
|
$7.92M |
| 2 |
Edwards Lifesciences
EW
|
$7.67M |
| 3 |
Cigna
CI
|
$6.73M |
| 4 |
IQVIA
IQV
|
$5.95M |
| 5 |
Labcorp
LH
|
$5.91M |
Top Sells
| 1 |
AKRX
Akorn, Inc.
AKRX
|
$11.9M |
| 2 |
Centene
CNC
|
$9.87M |
| 3 |
Incyte
INCY
|
$8M |
| 4 |
Ligand Pharmaceuticals
LGND
|
$6.69M |
| 5 |
ALR
Alere Inc
ALR
|
$5.78M |
Sector Composition
| 1 | Healthcare | 92.73% |
| 2 | Financials | 0.93% |
| 3 | Industrials | 0.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
LivaNova
LIVN
$3.08B
| $6.29M | 0.74% | 102,808 +38,619 | +60% | +$2.36M |
|
|
52
IQVIA
IQV
$32.4B
| $5.95M | 0.7% | +66,520 | New | +$5.95M |
|
53
BioMarin Pharmaceuticals
BMRN
$11.2B
| $5.9M | 0.7% | 65,000 | – | – |
|
54
Acadia Pharmaceuticals
ACAD
$4.38B
| $5.85M | 0.69% | 186,000 +141,000 | +313% | +$4.44M |
|
55
Cooper Companies
COO
$13.4B
| $5.75M | 0.68% | 24,000 +4,000 | +20% | +$958K |
|
56
MacroGenics
MGNX
$112M
| $5.54M | 0.66% | 316,418 +11,821 | +4% | +$207K |
|
|
CERN
57
DELISTED
Cerner Corp
CERN
| $4.95M | 0.59% | 74,500 | – | – |
|
|
HZNP
58
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.84M | 0.57% | 407,398 -91,367 | -18% | -$1.08M |
|
|
GNMK
59
DELISTED
GenMark Diagnostics, Inc
GNMK
| $4.79M | 0.57% | 405,178 +92,512 | +30% | +$1.09M |
|
60
Johnson & Johnson
JNJ
$427B
| $4.17M | 0.49% | 31,500 | – | – |
|
|
CBPO
61
DELISTED
China Biologic Products Holdings, Inc.
CBPO
| $4.1M | 0.48% | +36,250 | New | +$4.1M |
|
62
Dentsply Sirona
XRAY
$2.85B
| $3.27M | 0.39% | 50,500 +5,500 | +12% | +$357K |
|
|
ESRX
63
DELISTED
Express Scripts Holding Company
ESRX
| $3.16M | 0.37% | 49,500 | – | – |
|
64
McKesson
MCK
$85.4B
| $2.96M | 0.35% | 18,000 -6,000 | -25% | -$987K |
|
|
IPXL
65
DELISTED
Impax Laboratories, Inc.
IPXL
| $2.82M | 0.33% | +175,000 | New | +$2.82M |
|
66
ResMed
RMD
$40.2B
| $2.81M | 0.33% | 36,100 +28,100 | +351% | +$2.19M |
|
67
Halozyme
HALO
$8.56B
| $2.81M | 0.33% | 219,000 -51,000 | -19% | -$654K |
|
|
XENT
68
DELISTED
Intersect ENT, Inc
XENT
| $2.8M | 0.33% | 100,000 | – | – |
|
69
DexCom
DXCM
$29.5B
| $2.74M | 0.32% | 37,500 +1,400 | +4% | +$102K |
|
|
NUVA
70
DELISTED
NuVasive, Inc.
NUVA
| $2.72M | 0.32% | 35,304 +4,000 | +13% | +$308K |
|
71
CVS Health
CVS
$92.8B
| $2.69M | 0.32% | 33,400 | – | – |
|
72
Qiagen
QGEN
$10.1B
| $2.66M | 0.32% | +79,444 | New | +$2.66M |
|
|
TSRO
73
DELISTED
TESARO, Inc.
TSRO
| $2.66M | 0.31% | 19,000 +3,000 | +19% | +$420K |
|
74
Thermo Fisher Scientific
TMO
$186B
| $2.55M | 0.3% | 14,600 +1,600 | +12% | +$279K |
|
|
BLUE
75
DELISTED
bluebird bio
BLUE
| $2.32M | 0.27% | 22,100 -6,900 | -24% | -$725K |
|